T. Rowe Price Associates
DFTX

T. Rowe Price Associates’s Definium Therapeutics DFTX Stock Holding History

T. Rowe Price Associates’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219M Buy
4,652,032
+4,582,031
+6,546% +$113M 0.02% 484
2026
Q1 		$1.32M Buy
70,001
+17,771
+34% +$302K ﹤0.01% 2004
2025
Q4 		$700K Buy
52,230
+11,025
+27% +$136K ﹤0.01% 2244
2025
Q3 		$486K Buy
41,205
+4,874
+13% +$45.5K ﹤0.01% 2365
2025
Q2 		$236K Buy
36,331
+5,386
+17% +$35.4K ﹤0.01% 2638
2025
Q1 		$182K Sell
30,945
-368
-1% -$2.64K ﹤0.01% 2681
2024
Q4 		$218K Buy
31,313
+8,361
+36% +$57.5K ﹤0.01% 2642
2024
Q3 		$131K Hold
22,952
– – ﹤0.01% 2768
2024
Q2 		$0 Buy
+22,952
New +$201K ﹤0.01% 2986
2022
Q2 		– Sell
-1,966
Closed -$33K – 2995
2022
Q1 		$33K Buy
1,966
+434
+28% +$7.53K ﹤0.01% 2944
2021
Q4 		$32K Sell
1,532
-387
-20% -$12.4K ﹤0.01% 2950
2021
Q3 		$67K Buy
1,919
+66
+4% +$2.85K ﹤0.01% 2890
2021
Q2 		$96K Buy
+1,853
New +$97.3K ﹤0.01% 2853

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

T. Rowe Price Associates's DFTX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Definium Therapeutics (DFTX) stake by 6,546% in Q2 2026, buying an estimated $113M and bringing the position to 4,652,032 shares worth $219M. The position accounts for 0.02% of the portfolio, ranked #484.

T. Rowe Price Associates first reported a position in DFTX in Q2 2021 and has held it in 13 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • T. Rowe Price Associates held 4,652,032 shares of Definium Therapeutics worth $219M as of Q2 2026.
  • T. Rowe Price Associates bought 4,582,031 Definium Therapeutics shares in Q2 2026, an estimated $113M.
  • Definium Therapeutics made up 0.02% of T. Rowe Price Associates's portfolio in Q2 2026, its #484 holding.
  • T. Rowe Price Associates first reported a position in Definium Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.